{
    "id": "455f5a7a-2c80-4b4b-83a7-e3383c559d7d",
    "indications": "mesnex indicated prophylactic agent reducing incidence ifosfamide-induced hemorrhagic cystitis . limitation : mesnex indicated reduce risk hematuria due pathological conditions thrombocytopenia .",
    "contraindications": "mesnex may given fractionated dosing schedule three bolus intravenous injections single bolus injection followed two oral administrations mesnex tablets outlined . dosing schedule repeated day ifosfamide administered . ifosfamide adjusted , ratio mesnex ifosfamide maintained . ( 2 ) intravenous dosing schedule : 0 hours 4 hours 8 hours ifosfamide 1.2 g/m 2 - - mesnex injection 240 mg/m 2 240 mg/m 2 240 mg/m 2 intravenous oral dosing schedule : 0 hours 2 hours 6 hours ifosfamide 1.2 g/m 2 - - mesnex injection 240 mg/m 2 - - mesnex tablets - 480 mg/m 2 480 mg/m 2 maintain sufficient urinary output , required ifosfamide treatment , monitor urine presence hematuria . ( 2.3 )",
    "warningsAndPrecautions": "mesnex ( mesna ) injection 100 mg/ml •ndc 0338-1305-01 1 g multidose vial , box 1 vial 10 ml •ndc 0338-1305-03 1 g multidose vial , box 10 vials 10 ml store 20°c 25°c ( 68°f 77°f ) , excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] mesnex co-administered ifosfamide , refer ifosfamide prescribing information safe handling instructions . mesnex ( mesna ) tablets •ndc 67108-3565-9 400 mg scored tablets packaged box 10 tablets store 20°c 25°c ( 68°f 77°f ) , excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ]",
    "adverseReactions": "mesnex contraindicated patients known hypersensitive mesna excipients [ ( 5.1 ) ] .",
    "ingredients": [
        {
            "name": "MESNA",
            "code": "NR7O1405Q9"
        },
        {
            "name": "LACTOSE",
            "code": "J2B2A4N98G"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        }
    ],
    "organization": "Baxter Healthcare Company",
    "name": "MESNEX",
    "effectiveTime": "20191221",
    "indications_original": "MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. \n                  \n                     Limitation of Use: \n                  \n                  MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.",
    "contraindications_original": "MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below. The dosing schedule should be repeated on each day that ifosfamide is administered.  When the dosage of ifosfamide is adjusted, the ratio of MESNEX to ifosfamide should be maintained. ( 2 ) Intravenous Dosing Schedule: 0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m 2 -- -- MESNEX injection 240 mg/m 2 240 mg/m 2 240 mg/m 2 Intravenous and Oral Dosing Schedule: 0 Hours 2 Hours 6 Hours Ifosfamide 1.2 g/m 2 -- -- MESNEX injection 240 mg/m 2 -- -- MESNEX tablets -- 480 mg/m 2 480 mg/m 2 Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria. ( 2.3 )",
    "warningsAndPrecautions_original": "MESNEX (mesna) injection 100 mg/mL\n                  \n                     \n                        •NDC 0338-1305-01 1 g Multidose Vial, Box of 1 vial of 10 mL\n                     \n                        •NDC 0338-1305-03 1 g Multidose Vial, Box of 10 vials of 10 mL\n                     \n                         Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]\n                  \n                  If MESNEX is co-administered with ifosfamide, refer to the ifosfamide prescribing information for safe handling instructions.\n                  MESNEX (mesna) tablets\n                  \n                     \n                        •NDC 67108-3565-9 400 mg scored tablets packaged in box of 10 tablets\n                     \n                         Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]",
    "adverseReactions_original": "MESNEX is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see Warnings and Precautions (5.1)]."
}